London, 13 October 2015 -- Moody's Investors Service (Moody's) has today affirmed the Ba2 corporate family rating (CFR) and the Ba2-PD probability of default rating (PDR) of Grifols S.A. (Grifols), a global healthcare company primarily focused on blood plasma-derived products and transfusion medicine. Concurrently, Moody's also affirmed the Ba1 rating of the USD4.5 billion senior secured bank loans and the B1 rating of the unsecured USD1 billion notes issued by Grifols World Wide Operations Ltd. Moody's has changed the outlook to stable from negative.

Vollständigen Artikel bei Moodys lesen